Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items: 2019-2025

Historic Non-cash Items for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $7.0 million.

  • Kymera Therapeutics' Non-cash Items rose 20.14% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 20.14%. This contributed to the annual value of $6.2 million for FY2024, which is 87.51% down from last year.
  • Kymera Therapeutics' Non-cash Items amounted to $7.0 million in Q3 2025, which was up 1.65% from $6.9 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Non-cash Items high stood at $246.9 million for Q4 2021, and its period low was $1.6 million during Q1 2021.
  • Its 3-year average for Non-cash Items is $36.7 million, with a median of $7.0 million in 2025.
  • Per our database at Business Quant, Kymera Therapeutics' Non-cash Items tumbled by 98.80% in 2021 and then skyrocketed by 8,374.47% in 2022.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Non-cash Items stood at $246.9 million in 2021, then tumbled by 77.35% to $55.9 million in 2022, then decreased by 11.28% to $49.6 million in 2023, then slumped by 87.51% to $6.2 million in 2024, then grew by 20.14% to $7.0 million in 2025.
  • Its Non-cash Items was $7.0 million in Q3 2025, compared to $6.9 million in Q2 2025 and $87.9 million in Q1 2025.